References
- 1. DIEHL LF, KARNELL LH, MENCK HR. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999; 86:2684–2692.
- 2. SGAMBATI MT, LINET MS, DEVESA SS. Chronic lymphocytic leukemia: epidemiological, familial, and genetic aspects. In: Cheson BD, ed. Chronic lymphoid leukemias, 2nd ed. New York: Marcel Dekker, 2001:33–62.
- 3. ZENT CS, KYASA MJ, EVANS R, et al. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001; 92:1325–1330.
- 4. BINET JL, AUQUIER A, DIGIERO G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981; 48:198-206.
- 5. KYASA MJ, HAZLETT L, PARRISH RS, et al. Veterans with CLL/SLL have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004; 45:507-513.
- 6. ROBAK T. Second malignancies and Richter syndrome in patients with chronic lymphocytic leukemia. Hematology 2004; 9:387–400.
- 7. ZARRABI MH, GRUNWALK HW, ROSNER F. Chronic lymphocytic leukemia terminating in acute leukemia. Arch Intern Med 1977; 137:1059–1064.
- 8. ROBERTSON LE, ESTEY E, KANTARJIAN H, et al. Therapy related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia 1997; 8:2047–2051.
- 9. MORRISON VA, RAI KR, PETERSON BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002; 20:3878–3884.
- 10. BENE MC, CASTOLDI G, ORFAO A, et al. Proposal for the immunological classification of acute leukemias. Leukemia. 1995; 10:1783-6.
- 11. FLINN IW, NEUBERG DS, GRVER MR, et al. Phase III trial of fludarabine and cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25:793–798.